Novartis U.K. Site Closure Plan Shakes British R&D Community Anew
This article was originally published in The Pink Sheet Daily
Executive Summary
British R&D has taken another knock with news Novartis is closing its respiratory center in the county of West Sussex, England as part of the Swiss group’s wider R&D realignment worldwide. The planned move would mean the loss of up to 371 positions at the Horsham center.
You may also be interested in...
Prime Minister Cameron Plans To Boost U.K. Biotech With New "Catalyst" Fund, Early Patient Access Scheme
The U.K. plans to boost its life sciences sector with a series of measures, including a fund to support early-stage research and allowing early access to innovative medicines before regulatory approval.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.